-

Edgewise Therapeutics to Present at Upcoming Investor Conferences

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, announced today that members of its senior management team will participate in the following upcoming investor conferences:

Stifel 2023 Healthcare Conference
Presentation: Wednesday, November 15, 2023, at 10:55 am ET

Piper Sandler 35th Annual Healthcare Conference
Presentation: Wednesday, November 29, 2023, at 8:00 am ET

The presentations will be webcast live; links for the webcasts can be found on the Edgewise events page and will be accessible for replay following the presentations. It is recommended that users connect to the webcasts several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company’s deep expertise in muscle physiology is driving a new generation of first-in-class therapeutics. EDG-5506 is an orally administered skeletal myosin inhibitor in clinical trials in patients with Becker, Duchenne, and Limb-Girdle muscular dystrophies as well as McArdle Disease. EDG-7500, currently in a Phase 1 trial, is a novel cardiac sarcomere modulator for the treatment of HCM and other disorders of cardiac diastolic dysfunction. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X (formerly Twitter), Facebook, Instagram and Threads.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

Contacts

Investors & Media
Michael Carruthers
Chief Financial Officer
ir@edgewisetx.com

EDGEWISE THERAPEUTICS INC.

NASDAQ:EWTX
Details
Headquarters: Boulder, Colorado
CEO: Kevin Koch
Employees: 75
Organization: PUB

Release Versions

Contacts

Investors & Media
Michael Carruthers
Chief Financial Officer
ir@edgewisetx.com

Social Media Profiles
More News From EDGEWISE THERAPEUTICS INC.

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an investigational orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The conference will take place at the Hilton Anatole, Dallas, TX from March...

Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that u...

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2024 and recent business highlights. “Closing out 2024 with positive Phase 2 CANYON results, completing enrollment in GRAND CANYON and advancing CIRRUS-HCM, we are well positioned in 2025 across our muscular dystrophy and cardiovascular portfolio,” said Kevin Koch, Ph.D., President and Chief Exe...
Back to Newsroom